Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis

Описание к видео Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis

Host: John Mascarenhas, MD




Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.

Комментарии

Информация по комментариям в разработке

Похожие видео